Investigation of a Metabolism-Dependent Aryl Hydrocarbon Receptor (AhR) Off-Target Activation for a Drug Development Candidate and a Screening Strategy for De-Risking Backups

Clicks: 68
ID: 321685
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #37 of 154 articles by views in toxicological sciences : an official journal of the society of toxicology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 154 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
During lead optimization, off-target activation of the aryl hydrocarbon receptor (AhR) was identified for Compound 25. AhR is a xenobiotic-responsive transcription factor associated with adverse outcomes in rodents (and potentially humans) and modulation of drug metabolism. In rats, marked hepatic induction of AhR target genes, Cyp1a1 and Cyp1a2, was observed following repeat dosing and increased with study duration. Compound 25 was inactive in conventional AhR luciferase reporter assays but induced robust Cyp1a1 expression in metabolically competent rat and human HEPATOPAC® cultures, suggesting a metabolism-dependent mechanism. Extensive metabolite profiling demonstrated that Compound 25 undergoes complex oxidative and conjugative metabolism; however, specific AhR-active metabolite(s) could not be identified. AhR involvement was confirmed in vivo using AhR knockout and wild-type rats, in which Cyp1a1/2 induction occurred exclusively in wild-type animals. Chromatin immunoprecipitation further demonstrated increased AhR binding at Cyp1a1/2 promoters following Compound 25 treatment. In rat HEPATOPAC® cultures, siRNA-mediated knockdown of Por and Cyb5a attenuated Cyp1a1 induction, supporting a requirement for metabolic competence. Consistent with AhR pathway engagement, induction of CYP1A1 in human HEPATOPAC® was reduced by the AhR antagonist CH223191. Collectively, these findings demonstrate that AhR activation associated with Compound 25 is dependent on metabolic transformation and may not be detected in conventional reporter assays lacking metabolic capacity. This work highlights the value of metabolically competent hepatocyte models, combined with short-duration in vivo studies, for identifying and mitigating metabolism-dependent AhR liabilities during drug discovery.
Reference Key
openalex_W7169773685 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amy G. Aslamkhan, Wen Kang, Karin Otte, Alex Tamburino, Paul J. Ciaccio, Beatrice Sacre-Salem, Zoltán Erdős, Yuexia Liang, Richard W Gundersdorf, Bridget Becker, Keith Q. Tanis, Pippert Tr, Pam Lane, Binod Jacob, Kimberly B. Bleicher, Zhibin Wang, Ming Su, Stephen Pacchione, David Candito, Vladimir Simov, Peter H. Fuller, Matthew Fell, J Michael Ellis, R Foti, Kara Pearson, Frank D. Sistare, Warren E. Glaab
Are you one of these authors? Claim your profile
Journal toxicological sciences : an official journal of the society of toxicology
Year 2026
DOI
10.1093/toxsci/kfag083
URL
https://doi.org/10.1093/toxsci/kfag083
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.